Paul Chu Sin Chung1, Helen L Keyworth2, Elena Martin-Garcia3, Pauline Charbogne1, Emmanuel Darcq4, Alexis Bailey2, Dominique Filliol1, Audrey Matifas1, Grégory Scherrer5, Abdel-Mouttalib Ouagazzal1, Claire Gaveriaux-Ruff1, Katia Befort1, Rafael Maldonado3, Ian Kitchen2, Brigitte L Kieffer6. 1. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France. 2. Department of Biochemistry and Physiology, Faculty of Health and Medical Sciences, Institute of Biosciences and Medicine, University of Surrey, Guildford, Surrey, United Kingdom. 3. Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. 4. Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. 5. Department of Anesthesiology, Perioperative and Pain Medicine, Department of Molecular and Cellular Physiology, Department of Neurosurgery, Stanford Neurosciences Institute, Stanford University, Palo Alto, California. 6. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch, France.; Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.. Electronic address: brigitte.kieffer@douglas.mcgill.ca.
Abstract
BACKGROUND: The delta opioid receptor (DOR) is broadly expressed throughout the nervous system; it regulates chronic pain, emotional responses, motivation, and memory. Neural circuits underlying DOR activities have been poorly explored by genetic approaches. We used conditional mouse mutagenesis to elucidate receptor function in GABAergic neurons of the forebrain. METHODS: We characterized DOR distribution in the brain of Dlx5/6-CreXOprd1(fl/fl) (Dlx-DOR) mice and tested main central DOR functions through behavioral testing. RESULTS: The DOR proteins were strongly deleted in olfactory bulb and striatum and remained intact in cortex and basolateral amygdala. Olfactory perception, circadian activity, and despair-like behaviors were unchanged. In contrast, locomotor stimulant effects of SNC80 (DOR agonist) and SKF81297 (D1 agonist) were abolished and increased, respectively. The Dlx-DOR mice showed lower levels of anxiety in the elevated plus maze, opposing the known high anxiety in constitutive DOR knockout animals. Also, Dlx-DOR mice reached the food more rapidly in a novelty suppressed feeding task, despite their lower motivation for food reward observed in an operant paradigm. Finally, c-fos protein staining after novelty suppressed feeding was strongly reduced in amygdala, concordant with the low anxiety phenotype of Dlx-DOR mice. CONCLUSIONS: We demonstrate that DORs expressed in the forebrain mediate the described locomotor effect of SNC80 and inhibit D1-stimulated hyperactivity. Our data also reveal an unanticipated anxiogenic role for this particular DOR subpopulation, with a potential novel adaptive role. In emotional responses, DORs exert dual anxiolytic and anxiogenic roles, both of which may have implications in the area of anxiety disorders.
BACKGROUND: The delta opioid receptor (DOR) is broadly expressed throughout the nervous system; it regulates chronic pain, emotional responses, motivation, and memory. Neural circuits underlying DOR activities have been poorly explored by genetic approaches. We used conditional mouse mutagenesis to elucidate receptor function in GABAergic neurons of the forebrain. METHODS: We characterized DOR distribution in the brain of Dlx5/6-CreXOprd1(fl/fl) (Dlx-DOR) mice and tested main central DOR functions through behavioral testing. RESULTS: The DOR proteins were strongly deleted in olfactory bulb and striatum and remained intact in cortex and basolateral amygdala. Olfactory perception, circadian activity, and despair-like behaviors were unchanged. In contrast, locomotor stimulant effects of SNC80 (DOR agonist) and SKF81297 (D1 agonist) were abolished and increased, respectively. The Dlx-DORmice showed lower levels of anxiety in the elevated plus maze, opposing the known high anxiety in constitutive DOR knockout animals. Also, Dlx-DORmice reached the food more rapidly in a novelty suppressed feeding task, despite their lower motivation for food reward observed in an operant paradigm. Finally, c-fos protein staining after novelty suppressed feeding was strongly reduced in amygdala, concordant with the low anxiety phenotype of Dlx-DORmice. CONCLUSIONS: We demonstrate that DORs expressed in the forebrain mediate the described locomotor effect of SNC80 and inhibit D1-stimulated hyperactivity. Our data also reveal an unanticipated anxiogenic role for this particular DOR subpopulation, with a potential novel adaptive role. In emotional responses, DORs exert dual anxiolytic and anxiogenic roles, both of which may have implications in the area of anxiety disorders.
Authors: A J Roberts; L H Gold; I Polis; J S McDonald; D Filliol; B L Kieffer; G F Koob Journal: Alcohol Clin Exp Res Date: 2001-09 Impact factor: 3.455
Authors: D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz Journal: Psychopharmacology (Berl) Date: 2016-09-13 Impact factor: 4.530
Authors: Pauline Charbogne; Olivier Gardon; Elena Martín-García; Helen L Keyworth; Aya Matsui; Anna E Mechling; Thomas Bienert; Md Taufiq Nasseef; Anne Robé; Luc Moquin; Emmanuel Darcq; Sami Ben Hamida; Patricia Robledo; Audrey Matifas; Katia Befort; Claire Gavériaux-Ruff; Laura-Adela Harsan; Dominik von Elverfeldt; Jurgen Hennig; Alain Gratton; Ian Kitchen; Alexis Bailey; Veronica A Alvarez; Rafael Maldonado; Brigitte L Kieffer Journal: Biol Psychiatry Date: 2016-12-26 Impact factor: 13.382
Authors: Jean-François De Backer; Stéphanie Monlezun; Bérangère Detraux; Adeline Gazan; Laura Vanopdenbosch; Julian Cheron; Giuseppe Cannazza; Sébastien Valverde; Lídia Cantacorps; Mérie Nassar; Laurent Venance; Olga Valverde; Philippe Faure; Michele Zoli; Olivier De Backer; David Gall; Serge N Schiffmann; Alban de Kerchove d'Exaerde Journal: EMBO Rep Date: 2018-07-12 Impact factor: 8.807
Authors: Miriam Martínez-Navarro; David Cabañero; Agnieszka Wawrzczak-Bargiela; Anne Robe; Claire Gavériaux-Ruff; Brigitte L Kieffer; Ryszard Przewlocki; Josep E Baños; Rafael Maldonado Journal: Br J Pharmacol Date: 2020-02-10 Impact factor: 8.739
Authors: Zachariah Bertels; Wiktor D Witkowski; Sarah Asif; Kendra Siegersma; Richard M van Rijn; Amynah A Pradhan Journal: Headache Date: 2020-12-16 Impact factor: 5.887
Authors: Catherine M Cahill; Sarah V Holdridge; Shiwei Steve Liu; Lihua Xue; Claire Magnussen; Edmund Ong; Patrick Grenier; Anne Sutherland; Mary C Olmstead Journal: J Neurosci Res Date: 2020-07-05 Impact factor: 4.164
Authors: Mee Jung Ko; Terrance Chiang; Arbaaz A Mukadam; Grace E Mulia; Anna M Gutridge; Angel Lin; Julia A Chester; Richard M van Rijn Journal: Sci Signal Date: 2021-08-03 Impact factor: 8.192